About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The broad purpose of the Epidemiology and Public Health research group is contributing to increase the available scientific evidence regarding preventive interventions, to promote health, and prevent morbidity and mortality from major diseases. Our group uses epidemiological methods to study etiology, surveillance, and efficacy of these interventions. We are primarily focused on epidemiology and prevention of infectious diseases, in both individual and population levels. Main lines of research:
To characterize the epidemiology of multiple sclerosis (MS) in Catalonia, a prospective registry of new cases of MS in Catalonia was set up in 2009 with the participation of 21 hospitals throughout Catalonia. Prevalence and incidence studies based on this population-based registry are being performed.
Recently, and in collaboration with the Center of Multiple Sclerosis of Catalonia (Cemcat), we have set up a prospective registry of vaccination in patients with Immuno-Mediated Inflammatory Disease (IMID) who are candidates for biological treatment with the aim of evaluating vaccine immunogenicity and safety that will allow establishing the best vaccination strategy. In addition, we will study the prevalence and impact of comorbidity on Multiple Sclerosis prognosis.
IP: Susana Otero Romero
Includes the evaluation of risk factors, features, evolution, host, and impact of these infections. The group has been pioneer in the organization of a national prevalence surveillance project for nosocomial infections (EPINE) that is underway since 1990, allowing the analysis and monitoring of this data for investigational purposes. We are currently working in a multilevel analysis to evaluate the characteristics associated with nosocomial infections due to antibiotic resistant microorganisms, based on data of EPINE study (PI15/00787). We are also involved in the national study of device-related infections in intensive care units (ENVIN-Helics).
IP: Jose Angel Rodrigo Pendás
The group has participated in different phase II, III and IV clinical trials focused on the study of the immunogenicity, efficacy and safety of several preventive vaccines (e.g. influenza, human papilloma virus, hepatitis B, herpes zoster, respiratory syncytial virus…).
Currently, our group has expanded its line of research on the adjuvanted recombinant Herpes Zoster vaccine testing its safety and immunogenicity in pediatric immunosuppressed patients and adults =50 years of age with a prior episode of Herpes Zoster. Regarding observational studies, the group is leading a population study about the incidence of herpes zoster by risk groups (PI15/02273).
Our team has also started a new line of investigation for a Respiratory Syncytial Virus vaccine in healthy pregnant women.
IP: Xavier Martínez Gómez
IP: Begoña Benito Villabriga Collaborators: Carmen Escudero Iriarte, Ventura i Expósito, Laia, Susana Otero Romero, Ibane Abasolo Olaortua, Ignacio Ferreira González, José Antonio Barrabés Riu, Carlos Nos Llopis, Pablo Velasco Puyó, Jose Fernando Rodríguez Palomares, María Rosario Pérez- Torres Lobato, Sunny Malhotra Sareen, Perez Dueñas, Belen, Jaume Sastre Garriga, Joan López Hellin, Antonia Sambola Ayala, Jordi Rio Izquierdo, Nuria Rivas Gandara, Jordi Perez Rodon, Aroa Soriano Fernández, Manuel Comabella Lopez, Antonio Rodríguez Sinovas, Gisela Teixido Tura, Antonia Pijuan Domenech, Roser Ferrer Costa, Joaquin Seras Franzoso, Carmen Tur Gomez, Maria Cristina Díaz de Heredia Rubio, Laia Yañez Bisbe, Julia German Cortes, Maria Jose Pérez García, Miguel Segura Ginard, Diego Baranda Martínez-Abasca, Cristina Auger Acosta, Neus Bellera Gotarda, Herena Eixarch Ahufinger, M Mar Mañu Pereira, Deborah Pareto Onghena, Lorena Valero Arrese, Aitor Uribarri Gonzalez, Jordi Bañeras Rius, Alex Rovira Cañellas, Mar Tintore Subirana, Bruno García del Blanco, Maria Teresa Salcedo Allende, Marisol Ruiz Meana, Ana Belén Méndez Fernández, Xavier Montalban Gairín, Simon Schwartz Navarro, Anna Llort Sales, Carmen Espejo Ruiz, Raquel Hladun Alvaro, Angels Alcina Mila, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Ana Zabalza de Torres, Ariadna Boloix Amenós, Marc Miquel Moltó Abad, Javier Inserte Igual, Luciana Midaglia Fernandez, Elizabeth Pando Rau, Gabriela Guillén Burrieza, Cazurro Gutierrez, Ana Laura, Gómez Andrés, David, Alvaro Cobo Calvo, Alvaro Calabuig Goena, Joaquin Castillo Justribo, Lydia Dux-Santoy Hurtado, Lucas Moreno Martín-Retortillo, Andres Miguez Gonzalez, Josep Roma Castanyer, Laura Dos Subirá, Nicolás Miguel Fissolo, Maria Nazarena Pizzi, Tian Tian, Bou Teen, Diana, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Andrea Guala Funding agency: Instituto de Salud Carlos III Funding: 2494527.53 Reference: FORT23/00034 Duration: 01/01/2024 - 31/12/2027
IP: Susana Otero Romero Collaborators: Imane Boutitah Benyaich, Blanca Borras Bermejo, Anna Falcó Roget, Mar Tintore Subirana, Ana Zabalza de Torres, Jesus Trejo Zahinos Funding agency: Instituto de Salud Carlos III Funding: 115000 Reference: PI23/01654 Duration: 01/01/2024 - 31/12/2026
IP: Susana Otero Romero Collaborators: Juliana Esperalba Esquerra, Mar Tintore Subirana, Laia Pinos Tella, Marta Rodríguez Barranco, Luciana Midaglia Fernandez, Sonia Maria Uriona Tuma, Sonia Maria Uriona Tuma Funding agency: Instituto de Salud Carlos III Funding: 105270 Reference: PI19/01606 Duration: 01/01/2020 - 30/06/2024
IP: Juan Jose Gonzalez Lopez Collaborators: Manuel Hernández González, Jose Angel Rodrigo Pendás, Aina Aguiló Cucurull, Alba Mir Cros, Albert Moreno Mingorance, Andrea Martín Nalda, Nuria Serre Delcor, Josep Roca Grande, Laura Batlle Masó Funding agency: Instituto de Salud Carlos III Funding: 123420 Reference: PI21/00132 Duration: 01/01/2022 - 31/12/2024
PMID: 36991538 Journal: Influenza and Other Respiratory Viruses Year: 2023 Reference: Influenza Other Respir Viruses. 2023 Mar;17(3):e13098. doi: 10.1111/irv.13098. Impact factor: Publication type: Paper in international publication Authors: Dos Santos, Gael; Eckermann, Tamara; Martinez-Gomez, Xavier; Nwoji, Ugo; Parra, Jose; Salamanca de la Cueva, Ignacio et al. DOI: 10.1111/irv.13098
PMID: 37293849 Journal: EUROPEAN JOURNAL OF NEUROLOGY Year: 2023 Reference: Eur J Neurol. 2023 Jun 9. doi: 10.1111/ene.15809. Impact factor: Publication type: Paper in international publication Authors: Amato, Maria Pia; Campins, Magda; Farez, Mauricio; Filippi, Massimo; Hacohen, Yael; Hemmer, Bernhard; Juuti, Rosa; Lebrun-Frenay, Christine; Magyari, Melinda; Oreja-Guevara, Celia et al. DOI: 10.1111/ene.15809
PMID: 37293841 Journal: Multiple Sclerosis Journal Year: 2023 Reference: Mult Scler. 2023 Jun 9:13524585231168043. doi: 10.1177/13524585231168043. Impact factor: Publication type: Review in international publication Authors: Amato, Maria Pia; Campins, Magda; Farez, Mauricio; Filippi, Massimo; Hacohen, Yael; Hemmer, Bernhard; Juuti, Rosa; Lebrun-Frenay, Christine; Magyari, Melinda; Oreja-Guevara, Celia et al. DOI: 10.1177/13524585231168043
PMID: 37468284 Journal: NEUROLOGY Year: 2023 Reference: Neurology. 2023 Jul 19:10.1212/WNL.0000000000207664. doi: 10.1212/WNL.0000000000207664. Impact factor: Publication type: Paper in international publication Authors: Alvarez, Javier Villacieros; Arrambide, Georgina; Auger, Cristina; Carbonell-Mirabent, Pere; Castillo, Joaquin; Cobo-Calvo, Alvaro; Comabella, Manuel; Galan, Ingrid; Midaglia, Luciana Soledad; Mongay, Neus et al. DOI: 10.1212/WNL.0000000000207664
PMID: 34842496 Journal: Emerging Microbes & Infections Year: 2022 Reference: Emerg Microbes Infect. 2022 Dec;11(1):172-181. doi: 10.1080/22221751.2021.2011617. Impact factor: 7.163 Publication type: Paper in international publication Authors: Andres, Cristina; Pinana, Maria; Borras-Bermejo, Blanca; Gonzalez-Sanchez, Alejandra; Garcia-Cehic, Damir; Esperalba, Juliana; Rando, Ariadna; Zules-Ona, Ricardo-Gabriel; Campos, Carolina; Codina, Maria Gema et al. DOI: 10.1080/22221751.2021.2011617
PMID: 34596743 Journal: JOURNAL OF NEUROLOGY Year: 2022 Reference: J Neurol. 2022 Jan;269(1):452-459. doi: 10.1007/s00415-021-10823-z. Epub 2021 Oct 1. Impact factor: 4.849 Publication type: Paper in international publication Authors: Tur, Carmen; Auger, Cristina; Sastre-Garriga, Jaume; Montalban, Xavier; Cobo, Alvaro; Nos, Carlos; Arrambide, Georgina; Castillo, Joaquim; Rio, Jordi; Gasperini, Claudio et al. DOI: 10.1007/s00415-021-10823-z
PMID: 35105687 Journal: Neurology-Neuroimmunology & Neuroinflammation Year: 2022 Reference: Neurol Neuroimmunol Neuroinflamm. 2022 Feb 1;9(2). pii: 9/2/e1143. doi: 10.1212/NXI.0000000000001143. Print 2022 Mar. Impact factor: 8.485 Publication type: Paper in international publication Authors: Arrambide, Georgina; Zabalza, Ana; Nos, Carlos; Sastre-Garriga, Jaume; Tintore, Mar; Montalban, Xavier; Comabella, Manuel; Espejo, Carmen; Castillo, Joaquin; Otero-Romero, Susana et al. DOI: 10.1212/NXI.0000000000001143
PMID: 34554648 Journal: AMERICAN JOURNAL OF TRANSPLANTATION Year: 2022 Reference: Am J Transplant. 2022 Feb;22(2):673-675. doi: 10.1111/ajt.16855. Epub 2021 Oct 5. Impact factor: 8.086 Publication type: Letter or abstract Authors: Toapanta, Nestor; Esperalba, Juliana; Campos-Varela, Isabel; Pont, Teresa; Len, Oscar; Campins, Magda; Moreso, Francesc; Crespo, Elena; Munoz, Marina; Lopez, Manuel et al. DOI: 10.1111/ajt.16855
PMID: 34960209 Journal: Vaccines Year: 2021 Reference: Vaccines (Basel). 2021 Dec 10;9(12). pii: vaccines9121463. doi: 10.3390/vaccines9121463. Impact factor: 4.422 Publication type: Paper in international publication Authors: Pares-Badell, Oleguer, Martinez-Gomez, Xavier, Pinos, Laia, Borras-Bermejo, Blanca, Uriona, Sonia, Otero-Romero, Susana, Rodrigo-Pendas, Jose Angel, Cossio-Gil, Yolima, Agusti, Antonia, Aguilera, Cristina et al. DOI: 10.3390/vaccines9121463
PMID: 34384612 Journal: MEDICINA CLINICA Year: 2021 Reference: Med Clin (Barc). 2021 Jul 26. pii: S0025-7753(21)00433-4. doi: 10.1016/j.medcli.2021.07.005. Impact factor: 1.725 Publication type: Letter whit IF Authors: Escola-Verge, Laura, Borras-Bermejo, Blanca, Los-Arcos, Ibai, Esperalba, Juliana, Ferrer, Carmen, Fernandez-Hidalgo, Nuria et al. DOI: 10.1016/j.medcli.2021.07.005
PMID: 34018483 Journal: Eurosurveillance Year: 2021 Reference: Euro Surveill. 2021 May;26(20). doi: 10.2807/1560-7917.ES.2021.26.20.2001138. Impact factor: 6.307 Publication type: Paper in international publication Authors: Martin-Sanchez, Mario, Mercuriali, Lilas, Borras-Bermejo, Blanca, Lopez-Contreras, Joaquin, Vilella, Anna, Villar, Judit, Orcau, Angels, de Olalla, Patricia Garcia, Rius, Cristina, de Andres, Anna et al. DOI: 10.2807/1560-7917.ES.2021.26.20.2001138
PMID: 33761874 Journal: BMC Family Practice Year: 2021 Reference: BMC Fam Pract. 2021 Mar 25;22(1):56. doi: 10.1186/s12875-021-01414-y. Impact factor: 2.497 Publication type: Paper in international publication Authors: Coma, Ermengol, Mora, Nuria, Peremiquel-Trillas, Paula, Benitez, Mencia, Mendez, Leonardo, Mercade, Albert, Fina, Francesc, Fabregas, Mireia, Medina, Manuel et al. DOI: 10.1186/s12875-021-01414-y
PMID: 33160709 Journal: ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA Year: 2020 Reference: Enferm Infecc Microbiol Clin. 2020 Oct 13. pii: S0213-005X(20)30316-5. doi: 10.1016/j.eimc.2020.10.004. Impact factor: 1.654 Publication type: Letter whit IF Authors: Soler-Palacin, Pere, Borras-Bermejo, Blanca, Anton, Andres, Soriano-Arandes, Antoni et al. DOI: 10.1016/j.eimc.2020.10.004
PMID: 32663211 Journal: PLoS One Year: 2020 Reference: PLoS One. 2020 Jul 14;15(7):e0235466. doi: 10.1371/journal.pone.0235466. eCollection 2020. Impact factor: 2.74 Publication type: Paper in international publication Authors: de Los Santos, Juan Jose, Gomez I Prat, Jordi, Peremiquel-Trillas, Paula, Claveria Guiu, Isabel, Caro Mendivelso, Johanna, Choque, Estefa, Albajar Vinas, Pedro, Ascaso Terren, Carlos, Ouaarab Essadek, Hakima, Sulleiro, Elena et al. DOI: 10.1371/journal.pone.0235466
PMID: 32632084 Journal: Revista Espanola de Salud Publica Year: 2020 Reference: Rev Esp Salud Publica. 2020 Jul 7;94. Impact factor: 0.746 Publication type: Paper in national publication Authors: Ouaarab Essadek, Hakima, Borras Bermejo, Blanca, Caro Mendivelso, Johanna, Rodriguez Arjona, L Laia, Bisobe, Apolonia, Claveria Guiu, Isabel, Gomez I Prat, Jordi et al. DOI:
PMID: 32574139 Journal: EMERGING INFECTIOUS DISEASES Year: 2020 Reference: Emerg Infect Dis. 2020 Sep;26(9). doi: 10.3201/eid2609.202603. Epub 2020 Jun 23. Impact factor: 6.259 Publication type: Paper in international publication Authors: Abadias, Maria Jose, Roman, Antonio, Pumarola, Tomas, Campins, Magda, Almirante, Benito, Selvi, Marta, Martin, Elisabet, Anton, Andres, Esperalba, Juliana, Borras-Bermejo, Blanca et al. DOI: 10.3201/eid2609.202603
PMID: 31735582 Journal: Journal of healthcare quality research Year: 2019 Reference: J Healthc Qual Res. 2019 Nov - Dec;34(6):339-341. doi: 10.1016/j.jhqr.2019.06.005. Epub 2019 Nov 15. Impact factor: 0 Publication type: Letter or abstract Authors: Roel, E, Garcia-Diez, M, Borras Bermejo, B et al. DOI: 10.1016/j.jhqr.2019.06.005
PMID: 30606492 Journal: ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA Year: 2019 Reference: Enferm Infecc Microbiol Clin. 2019 Mar;37(3):215-217. doi: 10.1016/j.eimc.2018.11.012. Epub 2018 Dec 31. Impact factor: 1.685 Publication type: Letter or abstract Authors: Barcelo, Maria Estrella, Navarro-Royo, Elisa, Melendo-Perez, Susana, Fenoy-Alejandre, Marina, Morey-Olive, Miriam, Soler-Palacin, Pere, Soler-Palacin, Pere, Melendo-Perez, Susana, Mendoza-Palomar, Natalia, Fernandez-Polo, Aurora et al. DOI: 10.1016/j.eimc.2018.11.012
PMID: 31222620 Journal: JOURNAL OF COMMUNITY HEALTH Year: 2019 Reference: J Community Health. 2019 Aug;44(4):704-711. doi: 10.1007/s10900-019-00684-z. Impact factor: 1.572 Publication type: Paper in international publication Authors: Gomez I Prat, Jordi, Peremiquel-Trillas, Paula, Claveria Guiu, Isabel, Choque, Estefa, Oliveira Souto, Ines, Serre Delcor, Nuria, Sulleiro, Elena, Espasa, Mateu, Pastoret, Conxita, de Los Santos, Juan Jose et al. DOI: 10.1007/s10900-019-00684-z
PMID: 30509614 Journal: MEDICINA CLINICA Year: 2019 Reference: Med Clin (Barc). 2019 Apr 18;152(8):317-323. doi: 10.1016/j.medcli.2018.10.013. Epub 2018 Dec 1. Impact factor: 1.277 Publication type: Review in national publication Authors: Campins Marti, Magda, Borras Bermejo, Blanca, Armadans Gil, Lluis et al. DOI: 10.1016/j.medcli.2018.10.013
PMID: 30417657 Journal: Future Microbiology Year: 2018 Reference: Future Microbiol. 2018 Nov;13:1565-1573. doi: 10.2217/fmb-2018-0151. Epub 2018 Nov 12. Impact factor: 3.19 Publication type: Paper in international publication Authors: Campins-Marti, Magda, Andres, Cristina, Peremiquel-Trillas, Paula, Gimferrer, Laura, Isern, Anna, Pinana, Maria, Rodrigo-Pendas, Jose Angel, Codina, Maria Gema, Martin, Maria Del Carmen, Fuentes, Francisco et al. DOI: 10.2217/fmb-2018-0151
PhD student: Sandra Helena Suescún Carrero Director/s: Lluis Armadans Gil University: Year: 2022
PhD student: Luz Maria Vilca Yengle Director/s: Magda Campins Martí University: Universidad Autònoma de Barcelona Year: 2019
PhD student: Luz Maria Vilca Yengle Director/s: Magda Campins Martí University: Universidad Autònoma de Barcelona Year: 2018
PhD student: Yuani Miriam Román Morillo Director/s: Magda Campins Martí University: Universidad Autònoma de Barcelona Year: 2017
PhD student: José María Sánchez García Director/s: Josep Vaqué Rafart University: Universidad Autònoma de Barcelona Year: 2016
PhD student: Susana Otero Romero Director/s: Xavier Montalban Gairín, Jaume Sastre Garriga, Josep Vaqué Rafart University: Universidad Autònoma de Barcelona Year: 2016
PhD student: Maria Isabel Fernández Cano, Maria Isabel Fernández Cano, Maria Isabel Fernández Cano Director/s: Magda Campins Martí, Lluis Armadans Gil University: Universidad Autònoma de Barcelona Year: 2016
PhD student: Roser González Baulies, Roser González Baulies, Roser González Baulies Director/s: Magda Campins Martí University: Universidad Autònoma de Barcelona Year: 2015
PhD student: Dolors Carnicer Pont Director/s: Josep Vaqué Rafart University: Universidad Autònoma de Barcelona Year: 2015
PhD student: Flavia Maria Barkokebas Director/s: Josep Vaqué Rafart University: Universidad Autònoma de Barcelona Year: 2014
PhD student: Berta Ortiga Fontgivell Director/s: University: Universidad Autònoma de Barcelona Year: 2013
PhD student: Elvira Torné Vilagrasa Director/s: Josep Vaqué Rafart University: Universidad Autònoma de Barcelona Year: 2013
PhD student: Fernando Parrilla Valero Director/s: Josep Vaqué Rafart University: Universidad Autònoma de Barcelona Year: 2012
PhD student: Alberto Tobón Castaño Director/s: Josep Vaqué Rafart University: Universidad Autònoma de Barcelona Year: 2011
This strategy protects almost two thirds of patients. It also reduces the waiting time between vaccination and initiation of immune suppressive treatment.
El VHIR va participar activament en l'assaig clínic d'aquesta vacuna que avaluava la seguretat, la tolerabilitat i l'eficàcia.
A l'estudi hi participaran 200 persones voluntàries i es durà a terme a 10 hospitals espanyols, entre els quals Vall d’Hebron.
